Sartorius Extends Board Member René Fáber's Term Through 2031

The Supervisory Board of Sartorius AG has made a significant leadership decision by extending Dr. René Fáber's appointment to the Executive Board for an additional five-year term through December 31, 2031. Dr. Fáber, a 50-year-old polymer chemistry Ph.D. graduate from the Technical University of Munich, brings extensive institutional knowledge to his role, having joined the company as a scientist in 2002 and steadily progressed through various management positions before his initial Executive Board appointment in January 2019. As the leader responsible for the Bioprocess Solutions Division, his continued leadership signals stability and strategic continuity for this critical business unit, which provides essential single-use solutions for the production of biotech drugs, vaccines, and cell and gene therapies. This extension comes as Sartorius, a Göttingen-based international partner to the biopharmaceutical industry, continues to expand its global footprint with approximately 60 production and sales locations worldwide and a workforce exceeding 14,000 employees serving customers globally.

Sartorius operates through two main divisions: the Bioprocess Solutions Division under Dr. Fáber's purview and the Lab Products & Services Division, which focuses on innovative laboratory instruments and consumables for pharmaceutical, biopharmaceutical, and academic research institutions. The company reported substantial sales revenue of around 3.5 billion euros in 2025 and maintains an active growth strategy through acquisitions of complementary technologies. The announcement includes important financial calendar dates for stakeholders, with quarterly results scheduled for publication in April, July, and October of 2026. For further details, interested parties can view the original release on www.newmediawire.com or access additional resources such as the CV Rene Faber, the company's newsroom, and their LinkedIn profile for ongoing updates and corporate communications.

This leadership continuity announcement reflects Sartorius's commitment to maintaining experienced leadership as it navigates the rapidly evolving biopharmaceutical landscape. The company's focus on safer, faster, and more sustainable production solutions positions it at the forefront of supporting critical healthcare innovations, including vaccines and advanced therapies. With Dr. Fáber's deep understanding of both the scientific and business aspects of the industry—honed over more than two decades with the company—his extended tenure provides reassurance to investors, partners, and customers about the strategic direction of the Bioprocess Solutions Division. The timing of this announcement, ahead of key financial disclosures in 2026, suggests confidence in both current leadership and future growth prospects as Sartorius continues to play a vital role in the global healthcare supply chain.